Fig. 5

Life-year results within 10 years for first-line and second/further-line mechanisms’ PFS and OS (A Extrapolation results of first-line mechanisms’ PFS survival curves based on the Fractional polynomial model. B Extrapolation results of first-line mechanisms’ OS survival curves based on the Fractional polynomial model. C Fractional polynomial model result for first-line mechanisms’ PFS and OS. D Extrapolation results of second/further-lines mechanisms’ PFS survival curves based on the Fractional polynomial model. E Extrapolation results of second/further-lines mechanisms’ OS survival curves based on the Fractional polynomial model. F Fractional polynomial model result for second/further-line mechanisms’ PFS and OS). Abbreviations: AI, Aromatase inhibitor; AKTi, AKT inhibitor; Anti-VEGF, Anti-vascular endothelial growth factor; CDK4/6i, Cyclin-dependent kinase 4 and 6 inhibitors; EGFRi: Epidermal growth factor receptor inhibitor; HDACi, Histone deacetylase inhibitor; ICI, Immune checkpoint inhibitors; mTORi, Mammalian target of rapamycin inhibitor; Pi, Protease inhibitor; PI3Ki, Phosphatidylinositol 3-kinase inhibitor; SERD, Selective estrogen receptor degrader